Document and Entity Information
Document and Entity Information - $ / shares | May 10, 2019 | Mar. 31, 2019 |
Details | ||
Registrant Name | Kannalife Inc | |
Registrant CIK | 0001615999 | |
SEC Form | 10-Q | |
Period End date | Mar. 31, 2019 | |
Fiscal Year End | --12-31 | |
Trading Symbol | tygs | |
Tax Identification Number (TIN) | 462645343 | |
Number of common stock shares outstanding | 69,854,141 | |
Filer Category | Non-accelerated Filer | |
Current with reporting | Yes | |
Small Business | true | |
Emerging Growth Company | true | |
Ex Transition Period | false | |
Amendment Flag | false | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 | |
Entity Incorporation, State Country Name | Delaware | |
Entity Address, Address Line One | 3805 Old Easton Road | |
Entity Address, City or Town | Doylestown | |
Entity Address, State or Province | PA | |
City Area Code | 858 | |
Local Phone Number | 883-2642 | |
Entity Listing, Par Value Per Share | $ 0.0001 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Unaudited) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
CURRENT ASSETS: | ||
Cash and cash equivalents | $ 559,263 | $ 307,131 |
Marketable security (available for sale) | 1,525,000 | 2,579,640 |
Other receivables | 49,691 | 99,691 |
Due from related party, net | 9,799 | 16,334 |
Total Current Assets | 2,143,753 | 3,002,796 |
Property and equipment, net | 2,922 | 3,074 |
Security deposits | 17,121 | 17,121 |
TOTAL ASSETS | 2,163,796 | 3,022,991 |
CURRENT LIABILITIES: | ||
Accounts payable and accrued expenses | 269,355 | 283,996 |
Payroll and related liabilities | 247,396 | 246,067 |
Loan payable - related party | 42,092 | 16,173 |
Total Current Liabilities | 558,843 | 546,236 |
LONG TERM LIABILITIES: | ||
Loan payable - long term | 620,000 | 620,000 |
Loan payable - related party - long term | 0 | 25,822 |
Convertible notes payable - long term | 500,000 | 500,000 |
Total Long Term Liabilities | 1,120,000 | 1,145,822 |
TOTAL LIABILITIES | 1,678,843 | 1,692,058 |
STOCKHOLDERS' EQUITY: | ||
Common Stock, Value, Issued | 6,985 | 6,985 |
Additional paid-in capital | 6,384,274 | 6,381,755 |
Accumulated deficit | (5,898,016) | (5,052,051) |
Non-controlling interest | (8,290) | (5,756) |
TOTAL STOCKHOLDERS' EQUITY | 484,953 | 1,330,933 |
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 2,163,796 | 3,022,991 |
Commitments and contingencies | 0 | 0 |
Series A Preferred Stock | ||
STOCKHOLDERS' EQUITY: | ||
Preferred Stock, Value, Issued | 0 | 0 |
Series B Preferred Stock | ||
STOCKHOLDERS' EQUITY: | ||
Preferred Stock, Value, Issued | $ 0 | $ 0 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Unaudited) - Parenthetical - $ / shares | Mar. 31, 2019 | Dec. 31, 2018 |
Preferred Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 |
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 200,000,000 | 200,000,000 |
Common Stock, Shares, Issued | 69,854,141 | 69,854,141 |
Common Stock, Shares, Outstanding | 69,854,141 | 69,854,141 |
Series A Preferred Stock | ||
Preferred Stock, Shares Authorized | 75 | 75 |
Preferred Stock, Shares Issued | 75 | 75 |
Preferred Stock, Shares Outstanding | 75 | 75 |
Series B Preferred Stock | ||
Preferred Stock, Shares Authorized | 75 | 75 |
Preferred Stock, Shares Issued | 75 | 75 |
Preferred Stock, Shares Outstanding | 75 | 75 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
NET REVENUES: | ||
Grant Revenue | $ 49,291 | $ 30,006 |
TOTAL NET REVENUES | 49,291 | 30,006 |
OPERATING EXPENSES: | ||
Research and development | 101,278 | 23,766 |
General and administrative | 451,186 | 92,124 |
TOTAL OPERATING EXPENSES | 552,464 | 115,890 |
LOSS FROM OPERATIONS | (503,173) | (85,884) |
OTHER EXPENSE: | ||
Interest expense, net | (15,980) | (3,636) |
Loss on conversion of convertible debt | 0 | (61,815) |
Realized loss on marketable security | (228,039) | 0 |
Unrealized loss on marketable security | (101,307) | 0 |
TOTAL OTHER EXPENSE | (345,326) | (65,451) |
NET LOSS BEFORE INCOME TAX | (848,499) | (151,335) |
Income tax expense (benefit) | 0 | 0 |
NET LOSS | (848,499) | (151,335) |
Net loss attributable to noncontrolling interests | (2,534) | 0 |
Net loss attributable to Kannalife, Inc. | $ (845,965) | $ (151,335) |
Loss attributable to Kannalife, Inc. per common share - basic | $ (0.01) | $ 0 |
Loss attributable to Kannalife, Inc. per common share - diluted | $ (0.01) | $ 0 |
Weighted average common shares outstanding - basic | 69,854,141 | 60,089,401 |
Weighted average common shares outstanding - diluted | 69,854,141 | 60,089,401 |
Consolidated Consolidated State
Consolidated Consolidated Statement of Stockholders' Equity (Deficiency) - USD ($) | Series A Preferred Stock | Series B Preferred Stock | Common Stock | Additional Paid-in Capital | Retained Earnings | Noncontrolling Interest | Total |
Equity Balance, Starting at Dec. 31, 2017 | $ 0 | $ 0 | $ 5,328 | $ 2,683,776 | $ (5,988,866) | $ 0 | $ (3,299,762) |
Shares Outstanding, Starting at Dec. 31, 2017 | 0 | 0 | 53,281,932 | ||||
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments | $ 0 | $ 0 | $ 154 | 653,942 | 0 | 0 | 654,096 |
Stock Issued During Period, Shares, Conversion of Convertible Securities | 0 | 0 | 1,537,009 | ||||
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture | $ 0 | $ 0 | $ 551 | 2,812,260 | 0 | 0 | 2,812,811 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | 0 | 0 | 5,505,200 | ||||
Stock Issued During Period, Value, Issued for Services | $ 0 | $ 0 | $ 0 | 2,519 | 0 | 0 | 2,519 |
Stock Issued During Period, Shares, Issued for Services | 0 | 0 | 0 | ||||
Net Income (Loss) | $ 0 | $ 0 | $ 0 | 0 | (151,335) | 0 | (151,335) |
Shares Outstanding, Ending at Mar. 31, 2018 | 0 | 0 | 60,324,141 | ||||
Equity Balance, Ending at Mar. 31, 2018 | $ 0 | $ 0 | $ 6,033 | 6,152,497 | (6,140,201) | 0 | 18,329 |
Equity Balance, Starting at Dec. 31, 2018 | $ 0 | $ 0 | $ 6,985 | 6,381,755 | (5,052,051) | (5,756) | 1,330,933 |
Shares Outstanding, Starting at Dec. 31, 2018 | 75 | 75 | 69,854,141 | ||||
Stock Issued During Period, Value, Issued for Services | $ 0 | $ 0 | $ 0 | 2,519 | 0 | 0 | 2,519 |
Stock Issued During Period, Shares, Issued for Services | 0 | 0 | 0 | ||||
Net Income (Loss) | $ 0 | $ 0 | $ 0 | 0 | (845,965) | (2,534) | (848,499) |
Shares Outstanding, Ending at Mar. 31, 2019 | 75 | 75 | 69,854,141 | ||||
Equity Balance, Ending at Mar. 31, 2019 | $ 0 | $ 0 | $ 6,985 | $ 6,384,274 | $ (5,898,016) | $ (8,290) | $ 484,953 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 3 Months Ended | |
Mar. 31, 2019 | Mar. 31, 2018 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (848,499) | $ (151,335) |
used in operating activities: | ||
Loss on issuance of stock for conversion of notes payable and accrued salaries | 0 | 61,815 |
Realized loss on marketable security | 228,039 | 0 |
Unrealized loss on marketable security | 101,307 | 0 |
Depreciation | 152 | 0 |
Issuance of options for services | 2,519 | 2,519 |
Changes in operating assets and liabilities: | ||
Other receivables | 50,000 | 0 |
Accounts payable and accrued expenses | (14,641) | (76,327) |
Payroll and related liabilities | 1,329 | 524 |
Due from related party, net | 6,535 | 0 |
NET CASH USED IN OPERATING ACTIVITIES | (473,259) | (162,804) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Proceeds from sale of marketable securities | 725,294 | 0 |
NET CASH PROVIDED BY INVESTING ACTIVITIES | 725,294 | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Proceeds from notes payable - related party | 97 | 172,500 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 97 | 172,500 |
Net increase in cash | 252,132 | 9,696 |
Cash and cash equivalents, beginning of period | 307,131 | 4,326 |
Cash and cash equivalents, end of period | 559,263 | 14,022 |
NON-CASH ACTIVITIES: | ||
Issuance of common stock for conversion of notes payable and accrued interest | 0 | 236,104 |
Issuance of common stock for conversion of notes payable and accrued interest - related party | 0 | 356,176 |
Issuance of common stock for conversion of accrued salaries | $ 0 | $ 2,812,811 |
Note 1 - Organization and Natur
Note 1 - Organization and Nature of Operations | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
Note 1 - Organization and Nature of Operations | Note 1 Organization and Nature of Operations Kannalife, Inc. (the Company) was incorporated under the laws of the state of Delaware on March 25, 2013 under the name TYG Solutions Corp. The Company consummated a share exchange transaction on July 25, 2018 with Kannalife Sciences, Inc. (Kannalife), a privately held Delaware corporation formed in 2010, the accounting acquirer. Upon completion of the share exchange transaction, Kannalife is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Companys historical financial statements are those of Kannalife the surviving entity and accounting acquirer. All references that refer to (the Company or we or us or our) are Kannalife, unless otherwise differentiated. Kannalife is a phytomedical/pharmaceutical company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources, including the cannabis taxa. Share Exchange and Corporate Restructuring On July 25, 2018, the Company entered into a Share Exchange Agreement (the Share Exchange Agreement) with Kannalife Sciences, Inc., a Delaware corporation (Kannalife) and certain stockholders of Kannalife (the Kannalife Stockholders). Pursuant to the terms of the Share Exchange Agreement, the Company acquired approximately 99.7% of the issued and outstanding shares of Kannalife by means of a share exchange with the Kannalife Stockholders in exchange for 60,324,141 newly issued shares of the common stock of the Company (the Share Exchange), which increased the Company's issued and outstanding shares of common stock to 69,854,141. As a result of the Share Exchange, Kannalife became a 99.7% owned subsidiary of the Company, which on a going forward basis will result in consolidated financial reporting by the Company to include the results of Kannalife. The initial closing of the Share Exchange occurred concurrently with entry into the Share Exchange Agreement (the Initial Closing). After the Initial Closing and for a period of no more than 120 days thereafter, unless extended in the sole discretion of the Company, the Company may issue, on the same terms and conditions as those contained in the Share Exchange Agreement, additional shares of the common stock of the Company to Kannalife Stockholders that did not participate in the Initial Closing, provided that each additional Kannalife Stockholder becomes a party to the transaction documents (the Additional Closing). The Share Exchange has been accounted for as a reverse acquisition of the Company by Kannalife but in substance as a capital transaction, rather than a business combination since the Company had nominal operations and assets prior to and as of the closing of the Share Exchange. The former stockholders of Kannalife represent a significant constituency of the Companys voting power immediately following the Share Exchange and Kannalifes management has assumed operational, financial and governance control. The transaction is deemed a reverse recapitalization and the accounting is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded. For accounting purposes, Kannalife is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Companys historical financial statements are those of Kannalife. All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented. Company assets and liabilities pre-acquisition: Cash and cash equivalents $ 289,654 Note receivable 142,500 Total assets $ 432,154 Accounts payable and accrued expenses $ 20,504 Loan payable - related party - long term 41,995 Convertible notes payable 500,000 Total liabilities 562,499 Total liabilities assumed $ (130,345) The following summarized unaudited consolidated pro forma information shows the results of operations of the Company had the reverse acquisition occurred on January 1, 2018: Pro Forma (Unaudited) Three Months Ended March 31, 2018 Total revenues $ 30,006 Net loss $ (172,724) Net loss per common share, basic $ (0.00) Net loss per common share, diluted $ (0.00) The summarized unaudited consolidated pro forma results are not necessarily indicative of results which would have occurred if the acquisition had been in effect for the period presented. Further, the summarized unaudited consolidated pro forma results are not intended to be a projection of future results. Name Change On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State to change its name to Kannalife, Inc. The Company has concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change and is awaiting approval. The Companys name change and ticker change was reviewed and processed by FINRA and went effective January 17, 2019. Unaudited Interim Financial Information We have prepared the accompanying consolidated financial statements pursuant to the rules and regulations of the Securities and Exchange Commission (the SEC) for interim financial reporting. These consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals necessary for a fair presentation of our balance sheets, operating results, and cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for 2019. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States (GAAP) have been omitted in accordance with the rules and regulations of the SEC. These consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes. |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
Note 2 - Summary of Significant Accounting Policies | NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies used in the preparation of the consolidated financial statements are as follows: Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (ASC 810). The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Kannalife. The non-controlling interest in Kannalife represents the 0.30% equity interest held by the original shareholders of Kannalife before the share exchange. All significant consolidated transactions and balances have been eliminated in consolidation. The operations of Kannalife, Inc. are included in the consolidated financial statement from the date of the Share Exchange. Significant risks and uncertainties The Companys operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Companys products, the Companys ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Companys ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Companys ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Companys research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Companys stock, stock based compensation, and valuation allowance relating to the Companys deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made. Concentration Risks During the three months ended March 31, 2019, the Companys revenue had a concentration of 100% from one grant. The concentration of the Companys revenue creates a potential risk to future working capital in the event that the Company is not able to continue receiving the grant revenue. Revenue Recognition The FASB issued Accounting Standards Update (ASU) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The Company adopted ASC 606 effective January 1, 2018 using modified retrospective basis and the cumulative effect was immaterial to the consolidated financial statements. Revenue consists of research funding from the Companys National Institute of Health (NIH) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equitybased Payments to Non-Employees . Net Income (Loss) per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 5,150,000 for the three months ended March 31, 2019. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was zero (0) for the three months ended March 31, 2018. Research and Development In accordance with FASB ASC 730, Research and Development Recently Issued Authoritative Guidance In February 2016, the FASB issued ASU, Leases, which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: · · · · The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Companys lease population comprises of an office and lab, which is immaterial to the consolidated financial statements. As a result of the above, the adoption of ASC 842 did not have a material effect on the financial statements. The Company will review for the existence of embedded leases in future agreements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. This standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted as long as ASU 2014-09 has been adopted. The Company adopted the guidance on January 1, 2019. The adoption did not have a material impact on our consolidated financial statements. |
NOTE 3 - GOING CONCERN AND MANA
NOTE 3 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 3 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS | Note 3 Going Concern and Managements Liquidity Plans The Companys condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying condensed consolidated financial statements, the Company has had a net loss from operations of $503,173 and $85,884 for the three months ended March 31, 2019 and 2018, respectively. The net cash used in operations were $473,259 and $162,804 for the three months ended March 31, 2019 and 2018, respectively. Additionally, the Company had an accumulated deficit of $5,898,016 at March 31, 2019 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. As of March 31, 2019, we had approximately $559,000 in cash and cash equivalents. Additionally, we had $1,525,000 in marketable securities (available for sale). Management plans to raise additional capital through the sale of our marketable securities. We expect that between our existing cash, cash equivalents and marketable securities we will be able to sufficiently fund our operations and capital requirements for the next 15 months. The Companys history of recurring losses, and uncertainties as to whether its operations will become profitable and generate operating cash flows raise substantial doubt about its ability to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. |
NOTE 4 - FAIR VALUE MEASUREMENT
NOTE 4 - FAIR VALUE MEASUREMENTS | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 4 - FAIR VALUE MEASUREMENTS | Note 4 Fair Value Measurements The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts reported in the Companys consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate or short-term nature of these financial instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated. On March 7, 2014, Kannalife Sciences, Inc. (Kannalife) entered into an agreement with General Hemp LLC (General Hemp) through its wholly owned subsidiary Kannaway LLC (Kannaway) for certain rights and agreements to where each company would exchange 4.99% of each Companys equity, by way of a stock swap. As such, Kannalife would receive a 4.99% equity stake in Kannaway and Kannaway would receive 6,408,980 shares of restricted common stock of Kannalife. On or about April 2014, Kannalife delivered 6,408,980 of the aforementioned Kannalife restricted common stock to General Hemp on behalf of Kannaway and such shares were made to Kannaway as the beneficiary. The Company recorded the fair market value of the common stock at $256,359 or $0.04. The Company valued the shares based upon other transactions of the Company's common stock around the same time frame. The Company accounted for the transaction as a cost investment. On or about December 2015, Medical Marijuana, Inc. (MJNA) purchased Kannaway from General Hemp for which due to a dispute between the Company and General Hemp, the Company wasn't provided any of the consideration. On June 1, 2018, the Company received 41,583,333 shares of MJNA common stock pursuant to a settlement agreement effective July 15, 2017. MJNA is a significant shareholder of the Company and their Chief Executive Officer is also on the Company's Board of Directors. The following tables presents assets that are measured and recognized at fair value as of March 31, 2019, on a recurring basis: March 31, 2019 Level 1 Level 2 Level 3 Total Carrying Value Marketable securities Medical Marijuana, Inc. $ 1,525,000 - - $ 1,525,000 |
NOTE 5 - ACCRUED PAYROLL AND PA
NOTE 5 - ACCRUED PAYROLL AND PAYROLL TAXES | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 5 - ACCRUED PAYROLL AND PAYROLL TAXES | Note 5 Accrued Payroll and Payroll Taxes Accrued payroll and payroll taxes at March 31, 2019 and December 31, 2018 consisted of the following: 2019 2018 Payroll $ - $ - Payroll taxes 247,396 246,067 Totals $ 247,396 $ 246,067 As of March 31, 2019 and December 31, 2018, the Company has accrued payroll taxes in connection salaries paid and accrued to four officers of the Company. In July of 2018, the Company entered into a new employment agreement with our CEO. The initial term of the agreement is for two years and automatically renews for successive one year terms. In July of 2018, the Company entered into new employment agreements with three officers. The initial term of these agreements are for one year and automatically renew for successive six month terms. See Note 13 for discussion of accrued payroll converted into common stock. |
NOTE 6 - NOTES PAYABLE
NOTE 6 - NOTES PAYABLE | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 6 - NOTES PAYABLE | Note 6 Notes Payable During the year ended December 31, 2017, the Company borrowed $367,500 and issued a promissory note with a maturity date of October 18, 2017. This note was later amended to extend the maturity to April 18, 2019. During the year ended December 31, 2018, the Company borrowed an additional $352,500 and issued a promissory note with a maturity date of April 18, 2019. These loans incurred 3% interest per annum. On June 29, 2018, these notes were amended to extend the maturity date to July 1, 2020 and the interest rate was changed to 8% per annum. All accrued interest prior the amendment date was forgiven. Accrued interest related to these notes is $36,690 and $24,460 as of March 31, 2019 and December 31, 2018, respectively. Upon the consolidation of the Company and Kannalife, $100,000 of the above-mentioned borrowings was eliminated due to it being an intercompany transaction. The total, above mentioned, notes payable due is $620,000 as of March 31, 2019 and December 31, 2018. Total interest expense on notes payable, amounted to $12,230 and $3,636 for the three months ended March 31, 2019 and 2018, respectively. |
NOTE 7 - NOTES PAYABLE - RELATE
NOTE 7 - NOTES PAYABLE - RELATED PARTY | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 7 - NOTES PAYABLE - RELATED PARTY | NOTE 7 NOTES PAYABLE RELATED PARTY Prior to the share exchange agreement, the Company borrowed $25,822 and issued a promissory note with a maturity date of March 31, 2020. The loans represent working capital advances from shareholders, are unsecured, interest bearing 0.5%, and grant a security interest in the Companys assets as collateral. In March 2019, this note was amended and is now non-interest bearing. Accrued interest related to this note is $226 as of March 31, 2019 and December 31, 2018, respectively. As of December 31, 2018, due to related parties amounted to $16,173. The amounts due related parties represent working capital advances and fees for work performed by officers and shareholders, are unsecured, non-interest bearing and are due upon demand. Total interest expense on notes payable, amounted to $0 and $0 for the three months ended March 31, 2019 and 2018, respectively. |
NOTE 8 - CONVERTIBLE NOTES PAYA
NOTE 8 - CONVERTIBLE NOTES PAYABLE | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 8 - CONVERTIBLE NOTES PAYABLE | NOTE 8 CONVERTIBLE NOTES PAYABLE On May 15, 2015, the Company borrowed $35,000 and issued a convertible promissory note with a maturity date of April 30, 2016. The loan incurs 10% interest per annum. This note is convertible to the Companys common stock at a price of $1.00 per share. In addition, the Company issued 17,500 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $7,525 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. See below for discussion of settlement of liability through share exchange. On August 13, 2015, the Company borrowed $50,000 and issued a convertible promissory note with a maturity date of August 12, 2016. The loan incurs 10% interest per annum and increasing to 17% per annum in the event of a default. This note is convertible to the Companys common stock at a price of $1.00 per share. In addition, the Company issued 25,000 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $10,751 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. See below for discussion of settlement of liability through share exchange. On November 25, 2015, the Company borrowed $100,000 and issued a convertible promissory note with a maturity date of November 24, 2016. The loan incurs 10% interest per annum and increasing to 14% per annum in the event of a default. This note is convertible to the Companys common stock at a price of $1.00 per share. In addition, the Company issued 50,000 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $21,500 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. See below for discussion of settlement of liability through share exchange. Prior to the Share Exchange, the Company issued a convertible note to an investor, face value $500,000, in exchange for $500,000 in cash. The note is unsecured, bears interest at the rate of 3% per annum and matures on February 16, 2030. The note is convertible into common stock of the Company at $0.10 per share at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after giving effect to the conversion. See below for discussion of settlement of liability through share exchange. On January 3, 2018, prior to the Share Exchange, the Company issued 563,063 shares of common stock (on a post-Share Exchange basis) for the conversion of $236,104 convertible notes payable and related accrued interest. The Company recorded a loss of $3,515 on conversion based upon the difference between the fair market value of the Company's common stock and the liabilities relieved during the three months ended March 31, 2018. The Company determined that the transaction should be recorded at fair value due to the difference between the conversion price and the price per the agreements. |
NOTE 9 - CONVERTIBLE NOTES PAYA
NOTE 9 - CONVERTIBLE NOTES PAYABLE - RELATED PARTY | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 9 - CONVERTIBLE NOTES PAYABLE - RELATED PARTY | NOTE 9 CONVERTIBLE NOTES PAYABLE - RELATED PARTY On December 27, 2014, the Company borrowed $150,000 from a stockholder and issued a convertible promissory note with a maturity date of December 31, 2015. The loan incurs 10% interest per annum and increasing to 17% per annum in the event of a default. This note is convertible to the Companys common stock at a price of $1.00 per share. See below for discussion of settlement of liability through share exchange. During the year ended December 31, 2015, the Company borrowed $120,000 from the Chief Executive Officer and issued convertible promissory notes that are due on demand. The loans incur 10% interest per annum. These notes are convertible to the Companys common stock at a price of $1.00 per share. On November 20, 2015, the Company borrowed $5,000 from the Chief Executive Officer and issued a convertible promissory note that is due on demand. The loan incurs 10% interest per annum. This note is convertible to the Companys common stock at a price of $0.40 per share. During the year ended December 31, 2016, the Company borrowed $15,000 from the Chief Executive Officer and issued convertible promissory notes that are due on demand. The loans incur 10% interest per annum. These notes are convertible to the Companys common stock at a price of $0.40 per share. During the year ended December 31, 2016, the Company borrowed $10,000 from the Chief Executive Officer and issued convertible promissory notes with a maturity date of December 31, 2016. The loans incur 10% interest per annum and increasing to 17% per annum in the event of a default. These notes are convertible to the Companys common stock at a price of $0.40 per share. During the year ended December 31, 2017, the Company borrowed $20,000 from the Chief Executive Officer and issued convertible promissory notes with a maturity date of December 31, 2017. The loans incur 10% interest per annum and increasing to 17% per annum in the event of a default. These notes are convertible to the Companys common stock at a price of $0.40 per share. During the year ended December 31, 2017, the Company repaid $23,828 of principal and $16,522 of accrued interest towards the outstanding notes payable. As of December 31, 2017, $138,981 in principal and $0 of accrued interest was due. On January 3, 2018, prior to the Share Exchange, the Company converted these notes into 973,946 shares of common stock (on a post-Share Exchange basis) for the conversion of $356,176 convertible notes payable and related accrued interest. The difference of the $58,300 balance of the notes and the fair value of the shares issued was recorded as a loss on conversion of debt during the three months ended March 31, 2018. The Company determined that the transaction should be recorded at fair value due to the difference between the conversion price and the price per the agreements. |
NOTE 10 - COMMITMENTS AND CONTI
NOTE 10 - COMMITMENTS AND CONTINGENCIES | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 10 - COMMITMENTS AND CONTINGENCIES | Note 10 Commitments and Contingencies Legal Proceedings From time to time the Company may get involved in legal proceedings arising in the ordinary course of business. Other than as set forth in Legal Proceedings in Part II below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition. Occupancy Leases On April 1, 2014, the Company entered into a month to month lease arrangement for office space. The monthly rent payment is $2,700 and the security deposit is $15,000. On September 15, 2015, the Company entered into a one year lease arrangement for office space. The Company has amended this lease to extend the term through September 30, 2018. The On February 1, 2018, the Company entered into a month to month lease arrangement for laboratory space. The On July 1, 2018, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. On September 1, 2018, the Company subleased this office space to a third party. The Subleasee will pay 100% of rent for months September through November 2018 and will pay 50% of rent until expiration of lease on June 30, 2019. The Royalty Agreements On June 12, 2012, the Company entered into a Patent License Agreement with agencies of the United States Public Health Services within the Department of Health and Human Services (PHS). Under the License Agreement, PHS granted the Company an exclusive right to use and develop certain patents relating to Cannabinoids as Antioxidants and Neuroprotectants. In exchange for the License, the Company has agreed to the following payments: · · · · · · · · On December 31, 2014, the Company executed five exclusive pharmaceutical license agreements with the Companys CEO, the Companys CMO, three advisory board members of the Company, and an unrelated third party. These agreements provide the Company the worldwide exclusive rights to certain drug technologies and methods (and systems) for collection, processing and use of data for the dispensing of phyto-medical and botanically derived materials for consumption. The license agreements grant to the Company from the inventors the rights to develop, market, make, use, and sell certain drug formulations, which are applied to humans through the use of certain drug technology. In return for these exclusive rights from the inventors, the Company has agreed to compensate the inventors under the agreements with royalties ranging from 1.5% to 2.5% on all net sales by the Company of licensed products covered by a valid claim of a patent or patent application of the inventor patent rights. Additionally, the Company retains the rights to sublicense the drug formulations, and upon such sublicense shall pay the inventors from 1.5% up to 5% of all royalties and sublicense fees paid to the Company on account of sublicenses under the inventor patent rights and inventor technology rights, less all appropriate expenses associated with such sublicenses incurred by the Company. However, if the inventor supplies licensed products to sublicensees of the Company pursuant to such sublicenses, the inventor shall supply such licensed products at its cost. Prior to the Share Exchange this royalty agreement was terminated. |
NOTE 11 - RELATED PARTY TRANSAC
NOTE 11 - RELATED PARTY TRANSACTIONS | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 11 - RELATED PARTY TRANSACTIONS | Note 11 Related Party Transactions The Companys Chief Executive Officer shares the use of the leased office space for personal living quarters. From time to time the Company sends money to Golden Gate Capital (GGCP), a company owned by our CEO, for the advances of certain expenses and to be deposited into the bank account of Kannalife. Due to the timing of the funds transferred and expenses incurred, at times, there remains a balance due from GGCP. As of March 31, 2019, $9,799 is due from GGCP. Subsequent to the period end, GGCP has transferred all the remaining funds to Kannalife. As of the filing of these financial statements, there is no outstanding balance due from GGCP. See Notes 7, 9 and 13 for additional related party transactions. |
NOTE 12 - MARKETABLE SECURITY
NOTE 12 - MARKETABLE SECURITY | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 12 - MARKETABLE SECURITY | Note 12 Marketable Security On June 1, 2018, the Company received 41,583,333 shares of Medical Marijuana, Inc. (MJNA) common stock pursuant to a settlement agreement. In 2014, the Company entered into a revenue sharing agreement with Kannaway LLC, whereas, among the considerations and obligations the parties agreed to a share exchange, whereby the Company issued 6,408,980 shares of its common stock in exchange of 4.99% ownership of Kannaway. A significant shareholder of the Company owned the remaining ownership of Kannaway LLC. Subsequently, Kannaway was sold, by its parent company, to MJNA for 833,333,333 shares of MJNA common stock. The settlement agreement called for the release of all obligations in exchange for the issuance of 41,583,333 shares of common stock in MJNA to the Company. The investment in MJNA has been recorded as an investment in non-consolidated entities and is revalued every quarter with fluctuations in fair value recorded to earnings. The fair value of the investment is based on the closing price of the shares reported on the principal stock exchange on which they are traded. At March 31, 2019 the Company held 25,000,000 shares of MJNA which traded at a closing price of $0.061, or value of $1,525,000. For the three months ended March 31, 2019, an unrealized loss of $101,307 related to the investment in MJNA. See note 2 for additional information. |
NOTE 13 - STOCKHOLDERS' EQUITY
NOTE 13 - STOCKHOLDERS' EQUITY | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 13 - STOCKHOLDERS' EQUITY | Note 13 Stockholders Equity Series A Preferred Stock Kannalife Pre-Share Exchange In July 2018, prior to the Share Exchange, the Company converted 4,893,510 shares of preferred stock into 4,893,510 shares of common stock (on a post-Share Exchange basis). Series A Preferred Stock Effective May 3, 2018, the Companys Board of Directors authorized and designated 75 shares of the Companys Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Companys common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Companys board of directors and any annual or special meeting and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share. In July 2018, the Company issued 75 shares of Series A Preferred Stock, to Naturewell, Inc., an entity controlled by the former CEO of TYG Solutions, Inc., in exchange for $75,000. Series B Preferred Stock Effective May 3, 2018, the Companys Board of Directors authorized and designated 75 shares of the Companys Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Companys common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Companys board of directors and any annual or special meeting and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share. In July 2018, the Company issued 75 shares of Series B Preferred Stock, to our CEO, in exchange for $75,000. Common Stock The Company is authorized to issue 200,000,000 shares of $0.0001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders. On January 3, 2018, prior to the Share Exchange, the Company issued 5,505,200 shares of common stock (on a post-Share Exchange basis) to four officers, valued at $2,342,813, for the conversion of accrued salaries. The difference of $469,997 between the balance of accrued salaries and the fair value of the shares issued was recorded as a capital contribution recorded within additional paid-in capital. The transaction was viewed as being on behalf of the Company in connection with the pending share exchange transaction. In July 2018, the Company issued 2,030,000 shares of common stock, to an entity commonly controlled by the $500,000 convertible note holder, in exchange for $203,000. As of March 31, 2019 and December 31, 2018, there were 69,854,141 shares of common stock issued and outstanding, respectively. See Note 8 and 9 for discussion of the conversion of notes payable and accrued interest into commons stock. The Company determined fair value of its shares of common and preferred stock based on the price at which the Company was selling its shares of common and preferred stock to third party investors. Stock Options On September 1, 2017, the Company entered into an agreement for consulting services. As compensation the Company issued a stock options to purchase 100,000 shares of common stock at a price of $2.00 per share and are exercisable for five years. The stock option vests in equal monthly installments of 24 months. These options were valued at $20,154 using a Black-Scholes Options Pricing Model. For the three months ended March 31, 2019 and 2018, the Company recorded $2,519 as stock based compensation, which is included in the general and administrative expenses, in the statement of operations. |
NOTE 14 - SUBSEQUENT EVENTS
NOTE 14 - SUBSEQUENT EVENTS | 3 Months Ended |
Mar. 31, 2019 | |
Notes | |
NOTE 14 - SUBSEQUENT EVENTS | Note 14 Subsequent Events From April 1, 2019 through the issuance of these condensed consolidated financial statements, the Company sold an additional 6,512,000 shares of MJNA stock. The net proceeds from these sales were $320,869. The Company recognized a realized loss of $330,331 and an unrealized gain of $143,040 based on the closing price on May 8, 2019. |
Note 2 - Summary of Significa_2
Note 2 - Summary of Significant Accounting Policies: Basis of Presentation (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Basis of Presentation | Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. |
Note 2 - Summary of Significa_3
Note 2 - Summary of Significant Accounting Policies: Principles of Consolidation (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Principles of Consolidation | Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (ASC 810). The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Kannalife. The non-controlling interest in Kannalife represents the 0.30% equity interest held by the original shareholders of Kannalife before the share exchange. All significant consolidated transactions and balances have been eliminated in consolidation. The operations of Kannalife, Inc. are included in the consolidated financial statement from the date of the Share Exchange. |
Note 2 - Summary of Significa_4
Note 2 - Summary of Significant Accounting Policies: Significant risks and uncertainties (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Significant risks and uncertainties | Significant risks and uncertainties The Companys operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Companys products, the Companys ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Companys ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Companys ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Companys research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. |
Note 2 - Summary of Significa_5
Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Use of Estimates | Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Companys stock, stock based compensation, and valuation allowance relating to the Companys deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made. |
Note 2 - Summary of Significa_6
Note 2 - Summary of Significant Accounting Policies: Concentration Risks (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Concentration Risks | Concentration Risks During the three months ended March 31, 2019, the Companys revenue had a concentration of 100% from one grant. The concentration of the Companys revenue creates a potential risk to future working capital in the event that the Company is not able to continue receiving the grant revenue. |
Note 2 - Summary of Significa_7
Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Revenue Recognition | Revenue Recognition The FASB issued Accounting Standards Update (ASU) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The Company adopted ASC 606 effective January 1, 2018 using modified retrospective basis and the cumulative effect was immaterial to the consolidated financial statements. Revenue consists of research funding from the Companys National Institute of Health (NIH) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. |
Note 2 - Summary of Significa_8
Note 2 - Summary of Significant Accounting Policies: Stock Based Compensation (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Stock Based Compensation | Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equitybased Payments to Non-Employees . |
Note 2 - Summary of Significa_9
Note 2 - Summary of Significant Accounting Policies: Net Income (Loss) per Share (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Net Income (Loss) per Share | Net Income (Loss) per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was 5,150,000 for the three months ended March 31, 2019. The weighted average number of common stock equivalents not included in diluted income per share, because the effects are anti-dilutive, was zero (0) for the three months ended March 31, 2018. |
Note 2 - Summary of Signific_10
Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Research and Development | Research and Development In accordance with FASB ASC 730, Research and Development |
Note 2 - Summary of Signific_11
Note 2 - Summary of Significant Accounting Policies: Recently Issued Authoritative Guidance (Policies) | 3 Months Ended |
Mar. 31, 2019 | |
Policies | |
Recently Issued Authoritative Guidance | Recently Issued Authoritative Guidance In February 2016, the FASB issued ASU, Leases, which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update: · · · · The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Companys lease population comprises of an office and lab, which is immaterial to the consolidated financial statements. As a result of the above, the adoption of ASC 842 did not have a material effect on the financial statements. The Company will review for the existence of embedded leases in future agreements. In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. These amendments expand the scope of Topic 718, Compensation - Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. The ASU supersedes Subtopic 505-50, Equity - Equity-Based Payments to Non-Employees. This standard is effective for public companies for annual periods beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted as long as ASU 2014-09 has been adopted. The Company adopted the guidance on January 1, 2019. The adoption did not have a material impact on our consolidated financial statements. |
Note 1 - Organization and Nat_2
Note 1 - Organization and Nature of Operations: Schedule of pre-acquisition assets and liabilities (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Tables/Schedules | |
Schedule of pre-acquisition assets and liabilities | Cash and cash equivalents $ 289,654 Note receivable 142,500 Total assets $ 432,154 Accounts payable and accrued expenses $ 20,504 Loan payable - related party - long term 41,995 Convertible notes payable 500,000 Total liabilities 562,499 Total liabilities assumed $ (130,345) |
Note 1 - Organization and Nat_3
Note 1 - Organization and Nature of Operations: Schedule of Consolidated Pro-forma Information showing results of operations (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Tables/Schedules | |
Schedule of Consolidated Pro-forma Information showing results of operations | Pro Forma (Unaudited) Three Months Ended March 31, 2018 Total revenues $ 30,006 Net loss $ (172,724) Net loss per common share, basic $ (0.00) Net loss per common share, diluted $ (0.00) |
NOTE 4 - FAIR VALUE MEASUREME_2
NOTE 4 - FAIR VALUE MEASUREMENTS: Schedule of assets that are measured and recognized at fair value (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Tables/Schedules | |
Schedule of assets that are measured and recognized at fair value | March 31, 2019 Level 1 Level 2 Level 3 Total Carrying Value Marketable securities Medical Marijuana, Inc. $ 1,525,000 - - $ 1,525,000 |
NOTE 5 - ACCRUED PAYROLL AND _2
NOTE 5 - ACCRUED PAYROLL AND PAYROLL TAXES: Schedule of Accrued payroll and payroll taxes (Tables) | 3 Months Ended |
Mar. 31, 2019 | |
Tables/Schedules | |
Schedule of Accrued payroll and payroll taxes | 2019 2018 Payroll $ - $ - Payroll taxes 247,396 246,067 Totals $ 247,396 $ 246,067 |
Note 1 - Organization and Nat_4
Note 1 - Organization and Nature of Operations (Details) | 3 Months Ended |
Mar. 31, 2019 | |
Details | |
Entity Incorporation, State Country Name | Delaware |
Entity Incorporation, Date of Incorporation | Mar. 25, 2013 |
Entity Information, Former Legal or Registered Name | TYG Solutions Corp |
Note 1 - Organization and Nat_5
Note 1 - Organization and Nature of Operations: Schedule of pre-acquisition assets and liabilities (Details) | Mar. 31, 2019USD ($) |
Details | |
Pre-acquisition Assets, Cash and cash equivalents | $ 289,654 |
Pre-acquisition Assets, Note receivable | 142,500 |
Pre-acquisition Assets, Total assets | 432,154 |
Pre-acquisition Liabilities, Accounts payable and accrued expenses | 20,504 |
Pre-acquisition Liabilities, Loan payable - related party - long term | 41,995 |
Pre-acquisition Liabilities, Convertible notes payable | 500,000 |
Pre-acquisition Liabilities, Total liabilities | 562,499 |
Pre-acquisition Liabilities, Total liabilities assumed | $ (130,345) |
Note 1 - Organization and Nat_6
Note 1 - Organization and Nature of Operations: Schedule of Consolidated Pro-forma Information showing results of operations (Details) | 3 Months Ended |
Mar. 31, 2019USD ($)$ / shares | |
Details | |
Pro-forma Information, Total revenues | $ | $ 30,006 |
Pro-forma Information, Net income (loss) | $ | $ (172,724) |
Pro-forma Information, Net income (loss) per common share, basic | $ / shares | $ 0 |
Pro-forma Information, Net income (loss) per common share, diluted | $ / shares | $ 0 |
NOTE 3 - GOING CONCERN AND MA_2
NOTE 3 - GOING CONCERN AND MANAGEMENT'S LIQUIDITY PLANS (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Details | |||
LOSS FROM OPERATIONS | $ (503,173) | $ (85,884) | |
NET CASH USED IN OPERATING ACTIVITIES | (473,259) | $ (162,804) | |
Accumulated deficit | (5,898,016) | $ (5,052,051) | |
Marketable security (available for sale) | $ 1,525,000 | $ 2,579,640 |
NOTE 4 - FAIR VALUE MEASUREME_3
NOTE 4 - FAIR VALUE MEASUREMENTS: Schedule of assets that are measured and recognized at fair value (Details) | Mar. 31, 2019USD ($) |
Fair Value, Inputs, Level 1 | |
Marketable securities - Medical Marijuana, Inc | $ 1,525,000 |
Fair Value, Inputs, Level 2 | |
Marketable securities - Medical Marijuana, Inc | 0 |
Fair Value, Inputs, Level 3 | |
Marketable securities - Medical Marijuana, Inc | 0 |
Marketable securities - Medical Marijuana, Inc | $ 1,525,000 |
NOTE 5 - ACCRUED PAYROLL AND _3
NOTE 5 - ACCRUED PAYROLL AND PAYROLL TAXES: Schedule of Accrued payroll and payroll taxes (Details) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Details | ||
Payroll | $ 0 | $ 0 |
Payroll taxes | 247,396 | 246,067 |
Totals | $ 247,396 | $ 246,067 |
NOTE 7 - NOTES PAYABLE - RELA_2
NOTE 7 - NOTES PAYABLE - RELATED PARTY (Details) - USD ($) | Mar. 31, 2019 | Dec. 31, 2018 |
Details | ||
Loan payable - related party | $ 42,092 | $ 16,173 |
NOTE 10 - COMMITMENTS AND CON_2
NOTE 10 - COMMITMENTS AND CONTINGENCIES (Details) | 3 Months Ended |
Mar. 31, 2019 | |
Other commitment 1 | |
Other Commitments, Description | On April 1, 2014, the Company entered into a month to month lease arrangement for office space |
Other commitment 2 | |
Other Commitments, Description | On September 15, 2015, the Company entered into a one year lease arrangement for office space |
Other commitment 3 | |
Other Commitments, Description | On February 1, 2018, the Company entered into a month to month lease arrangement for laboratory space |
Other commitment 4 | |
Other Commitments, Description | On July 1, 2018, the Company entered into a one year lease arrangement for office space |
NOTE 13 - STOCKHOLDERS' EQUITY
NOTE 13 - STOCKHOLDERS' EQUITY (Details) - USD ($) | 3 Months Ended | ||
Mar. 31, 2019 | Mar. 31, 2018 | Dec. 31, 2018 | |
Common Stock, Shares Authorized | 200,000,000 | 200,000,000 | |
Common Stock, Par or Stated Value Per Share | $ 0.0001 | $ 0.0001 | |
Common Stock, Shares, Issued | 69,854,141 | 69,854,141 | |
Common Stock, Shares, Outstanding | 69,854,141 | 69,854,141 | |
Stock Issued During Period, Value, Issued for Services | $ 2,519 | $ 2,519 | |
Additional Paid-in Capital | |||
Stock Issued During Period, Value, Issued for Services | $ 2,519 | $ 2,519 |
NOTE 14 - SUBSEQUENT EVENTS (De
NOTE 14 - SUBSEQUENT EVENTS (Details) - Event 1 | 3 Months Ended |
Mar. 31, 2019USD ($)shares | |
Subsequent Event, Description | Company sold an additional 6,512,000 shares of MJNA stock |
Sale of Stock, Description of Transaction | Company sold an additional 6,512,000 shares |
Shares, Issued | shares | 6,512,000 |
Issuance of common stock for conversion of notes payable and accrued interest | $ 320,869 |
Equity Securities, FV-NI, Realized Loss | 330,331 |
Equity Securities, FV-NI, Unrealized Gain (Loss) | $ 143,040 |